DoH introduces advanced gene-editing therapy for sickle cell disease and thalassemia
ABU DHABI (ALETIHAD)The Department of Health – Abu Dhabi (DoH) has announced the introduction of CASGEVY, the first CRISPR/Cas9 gene-editing therapy in the UAE, offering innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).The innovative treatment, provided by Abu Dhabi Stem Cells Center (ADSCC), in coordination with DoH and in collaboration with Vertex Pharmaceuticals, a leading biotechnology company, positions Abu Dhabi as a leading destination for life sciences. The first patient is scheduled to begin the groundbreaking therapy at Yas Clinic Hospital in April of this year.CRISPR/Cas9 gene-editing is an innovative technology that enables precise genome editing to treat certain genetic diseases by targeting and altering specific DNA sequences. CASGEVY is a one-time treatment tailored for each patient by extracting the patient's own hematopoietic stem cells, genetically editing them in the lab, and then re-implanting them into the patient's body to provide long-term positive effects.In line with DoH's commitment to fostering innovation and ensuring the health and safety of patients in the emirate, the department has established regulations and guidelines for the management of gene therapies, according to the highest international standards. The treatment has been included in insurance coverage in accordance with established regulations and standards.Commenting on the innovative treatment, Dr. Noura Khamis Al Ghaithi, Undersecretary, DoH, said: 'The Department of Health – Abu Dhabi remains dedicated to safeguarding the health and well-being of our community while continuously enhancing the quality of care. Our goal is to establish the world's most efficient healthcare system through the adoption of the latest innovations and promising technologies. By harnessing genomic sciences, we aim to develop cutting-edge therapeutic solutions to complex health challenges, solidifying Abu Dhabi's position as a global leader in healthcare, life sciences, and innovation.'For her part, Dr. Maysoon Al Karam, Chief Medical Officer at ADSCC and Yas Clinic, said: "Partnerships with leading biotechnology companies such as Vertex Pharmaceuticals represent a significant milestone in ADSCC's global mission, aligning with the UAE's vision and strategic health priorities. She explained, "Patients with genetic disorders such as thalassemia and sickle cell disease will greatly benefit from this revolutionary treatment, which we aim to offer as one of the first advanced gene therapies in the country. As the UAE's leading cellular research institution and the UAE's first FACT-accredited center, we strive through such partnerships to drive medical innovation, developing treatments for a range of critical diseases, and reinforcing Abu Dhabi's position as a global hub for life sciences, in line with the UAE's leadership vision.Hisham Hagar, Senior Country Manager at Vertex GCC, said: 'We are delighted to partner with the Abu Dhabi Stem Cells Center, the UAE's leading cellular research institution, to bring the world's first CRISPR/Cas9 gene-editing medicine to patients in the UAE. This partnership represents a significant step toward bringing transformative medicines to patients in the UAE for serious diseases like SCD and TDT, ultimately advancing our mission to improve patients' lives in the UAE.'
The Emirates Drug Establishment (EDE) in the UAE, has granted a market authorisation for CASGEVY to treat patients aged 12 years and older who suffer from sickle cell disease with recurrent vaso-occlusive crises, as well as transfusion-dependent thalassemia.
Source: Aletihad - Abu Dhabi
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Business
8 hours ago
- Arabian Business
Abu Dhabi launches newborn genetic screening programme to detect 815 childhood conditions
The Department of Health – Abu Dhabi (DoH) has launched the Newborn Genetic Screening Programme, one of the most comprehensive of its kind globally, offering whole genome sequencing to screen for more than 815 treatable childhood genetic conditions. The initiative, launched in alignment with the Emirati Genome Council's vision for personalised and precision healthcare, marks a step towards genomics-driven medicine in the UAE. It enables early detection, tailored interventions, and improved health outcomes for newborns. In its first phase, the programme has been introduced at Kanad Hospital and Danat Al Emarat Hospital, in partnership with M42, as a voluntary option. It is set to expand across all maternity hospitals in the emirate to cover UAE nationals and children of Emirati mothers. By testing cord blood samples at birth with parental consent, the programme screens for metabolic disorders, immunodeficiencies, hematologic conditions, and rare diseases such as spinal muscular atrophy, which can be treated with gene therapy. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Healthcare begins long before symptoms appear, and today, empowered by science and technology, we can act earlier than ever before. This programme reflects Abu Dhabi's commitment to leveraging innovation to serve our community, starting from the first days of life. Through early detection, personalised care, and strategic foresight, we are building a future of healthier generations and reinforcing Abu Dhabi's position as a global leader in proactive, precision healthcare.' Dr. Mohamed Al Ameri, Acting Director of Genome and Biobank Division, Department of Health – Abu Dhabi, said: 'As we work to integrate genomics into our preventative healthcare infrastructure, we aim to expand this initiative to all maternity hospitals in the emirate, demonstrating how genomics can reshape healthcare, shifting from a one-size-fits-all model to a precise, proactive, and personalised approach that improves patient outcomes.' To support the rollout, DoH held workshops with stakeholders to review the gene panel and patient journey, and trained 16 paediatricians and neonatologists on genetic counselling practices. Results are reported within 21 days, with genetic counselling and referrals provided if actionable findings are identified. The Newborn Genetic Screening Programme builds on initiatives under the Emirati Genome Programme, including premarital screening, and is part of a broader strategy to integrate genomics into family health to reduce the prevalence of genetic diseases and support informed decision-making.
Zawya
12 hours ago
- Zawya
Cleveland Clinic Abu Dhabi introduces breakthrough stroke treatment
Cleveland Clinic Abu Dhabi has performed the region's first procedure using the Artisse Intrasaccular Flow Modulator, a pioneering medical implant for treating wide-necked brain aneurysms. Designated by the Department of Health – Abu Dhabi as a Centre of Excellence for stroke, the hospital is the first in the Middle East and North Africa to adopt the technology. The minimally invasive procedure involves inserting a catheter through a blood vessel to deploy a mesh device that seals the aneurysm, preventing rupture and reducing the risk of stroke. The first patient treated with the device at the hospital showed successful aneurysm closure after three months, underscoring the technology's potential for safer and more effective outcomes. Fayeza Al Yafie, Executive Director of Healthcare Quality at the Department of Health – Abu Dhabi, said the milestone reflects the emirate's commitment to innovation and advanced patient care. Khalil Zahra, Staff Physician in Neurosurgery at Cleveland Clinic Abu Dhabi, said the new approach enhances treatment for complex aneurysms while reducing the need for invasive surgery. Since launching the UAE's first multi-organ transplant programme in 2017, Cleveland Clinic Abu Dhabi has become a leading referral centre for advanced care. The adoption of this device further strengthens its role as a hub for neurological innovation in the region.
Zawya
12 hours ago
- Zawya
Cleveland Clinic Abu Dhabi provides advanced first-of-its-kind stroke treatment in MENA region
As designated Center of Excellence for stroke, the hospital continues to expand access to safer, minimally invasive treatments for complex neurovascular conditions. The hospital's multidisciplinary team of neurological experts delivers highly specialized care using advanced imaging and catheter-based precision to reduce surgical risks and improve long-term outcomes. Abu Dhabi: Cleveland Clinic Abu Dhabi has set a new standard in the treatment of brain aneurysms in the Middle East and North Africa (MENA) region, adopting the first Artisse Intrasaccular Flow Modulator, a novel medical implant for wide-necked intracranial aneurysms. Designated by the Department of Health – Abu Dhabi as a Centre of Excellence (CoE), this milestone underscores the hospital's position for stroke as it continues to advance medical technology and deliver world-class care for patients. Cerebral aneurysms, or strokes, occur when a weakened area in a blood vessel wall in the brain causes a bulge or balloon-like expansion, posing significant risks if untreated, including subarachnoid hemorrhage, a type of stroke caused by bleeding in the brain. Traditionally, treating aneurysms requires invasive open surgery. However, recent advancements in minimally invasive procedures have transformed how these conditions are managed, offering safer and more effective options for patients. The procedure begins with a minimally invasive technique where a catheter is inserted through the patient's blood vessels, typically from the groin or arm, to reach the aneurysm in the brain. Using advanced 3D imaging and angiograms, physicians can visualize and assess the aneurysm with precision. Once positioned, the unique mesh device is deployed into the aneurysm and fills it, preventing blood from entering, reducing the risk of rupture and associated complications like subarachnoid hemorrhage. This innovative technique is particularly useful for aneurysms with wide necks, which are typically challenging to treat using traditional methods. The device stays in place permanently, eliminating the need for further invasive surgery while providing long-term protection against rupture. The procedure itself can take between two to eight hours, depending on the complexity of the aneurysm. Following the treatment, patients undergo follow-up imaging at regular intervals, typically at three and six months, to ensure the device is effectively treating the aneurysm. For the first patient treated with this device at Cleveland Clinic Abu Dhabi, follow-up imaging at three months showed successful occlusion of the aneurysm, demonstrating the promising potential of this innovative treatment. This innovative technology marks a significant leap forward in cerebral aneurysm treatment. Unlike traditional methods that rely on multiple coils or filaments to occlude the aneurysm, this unique device uses a single, intricately designed mesh structure that effectively seals off the aneurysm, preventing blood flow and drastically reducing the risk of rupture. The adoption of the technology at Cleveland Clinic Abu Dhabi enhances current treatment options and paves the way for future advancements in neurological care. Dr. Fayeza Al Yafie, Executive Director of the Healthcare Quality Sector at the Department of Health – Abu Dhabi (DoH), said: 'Centers of Excellence in Abu Dhabi continue to affirm their commitment to enhancing the healthcare system by providing specialized care and utilizing the emirate's advanced infrastructure. Abu Dhabi's dynamic regulatory environment encourages research and innovation in the continuous development and attraction of talent, as well as cutting-edge technologies and treatments that contribute to the health and safety of community members. We congratulate Cleveland Clinic Abu Dhabi on this milestone and look forward to working together to position the healthcare system in the emirate among the best and most intelligent globally.' Dr. Khalil Zahra, Staff Physician, Neurosurgery, Neurological Institute at Cleveland Clinic Abu Dhabi, said: "The introduction of this novel stroke technology in our region enhances our ability to treat complex aneurysms and demonstrates our ongoing commitment to bringing the latest medical advancements to our patients. This technology, combined with our multidisciplinary approach to patient care, ensures that we continue to provide world-class treatment options for even the most challenging neurological conditions. The successful implementation of the device in its first procedure marks a new era in the treatment of cerebral aneurysms, offering our patients a safer, more efficient, and less invasive treatment option." Dr Zahra added: 'This technology serves as a springboard for further innovation in our field. Combining our experience with the new technology, we will inform future research initiatives, potentially leading to even more refined treatment methods for complex cerebrovascular conditions. Moreover, as we gather long-term data on patient outcomes, we expect to contribute valuable insights to the global neurosurgical community, further solidifying Cleveland Clinic Abu Dhabi's position as a leader in neurological care and research in the MENA region.' The successful implementation of the device at Cleveland Clinic Abu Dhabi is a testament to the Neurological Institute's comprehensive, multidisciplinary approach to care. By bringing together experts from various specialties, including neurosurgery, interventional neuroradiology, and neurology, this collaborative model ensures that each patient receives personalized treatment plans that leverage the full potential of cutting-edge technologies. As designated Centre of Excellence for stroke, Cleveland Clinic Abu Dhabi was chosen as the launch site for this breakthrough device. The hospital remains at the forefront of neurological care in the MENA region, continuously seeking innovative solutions to improve patient outcomes and quality of life. The addition of the Artisse Intrasaccular Flow Modulator device to the hospital's treatment arsenal is yet another testament to its leadership in the field. About Cleveland Clinic Abu Dhabi Cleveland Clinic Abu Dhabi is a multispecialty hospital located on Al Maryah Island in Abu Dhabi, UAE. As an extension of Cleveland Clinic in the U.S., it is uniquely designed to address the complex and critical care needs of the UAE and the broader region. The hospital is organized into specialized Institutes, including Heart, Vascular & Thoracic; Neurological; Cancer; Digestive Disease; Medical Subspecialties; Integrated Surgical Subspecialties; Integrated Hospital Care; and Diagnostic. Celebrating its 10th anniversary in 2025, Cleveland Clinic Abu Dhabi is a 405-bed hospital, including 321 acute care beds, 84 critical care beds, four royal suites, and 26 operating rooms. Its state-of-the-art facilities provide patients in the region with direct access to world-class healthcare providers and Cleveland Clinic's renowned model of care. The hospital is also home to the Fatima bint Mubarak Center, a dedicated cancer center offering comprehensive diagnostics and advanced treatment across 24 clinical departments, covering a range of cancer subspecialties and programs. Committed to medical innovation, Cleveland Clinic Abu Dhabi integrates robotics across specialties, pioneers' endovascular therapy and hybrid procedures, and offers comprehensive programs in heart failure, heart transplantation, and limb salvage. Licensed by the Department of Health – Abu Dhabi as a designated research and teaching facility, Cleveland Clinic Abu Dhabi drives medical innovation through clinical trials and advanced research to enhance patient care. It is the first hospital in the UAE accredited by both the Accreditation Council for Graduate Medical Education International (ACGMEI) and the Accreditation Council for Continuing Medical Education (ACCME), offering residency and fellowship programs, undergraduate health professional training, and Continuing Medical Education (CME). M42 is a global, tech-enabled healthcare company based in Abu Dhabi, operating at the forefront of medical advancement. Media contact Farah Chaaban –
